Skilled motor deficits in rats induced by ventrolateral striatal dopamine depletions: Behavioral and pharmacological characterization

Brain Research

Volumn 732, Issue 1-2, 1996, Pages 186-194

  Cousins, Michael S ^a   Salamone, John D ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

dopamine; L DOPA; motor; Parkinson; putamen; striatum

Indexed keywords

LEVODOPA; OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; PUTAMEN; RAT;

EID: 0030565585     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-8993(96)00519-7     Document Type: Article

References (63)

1. Alexander G.E., Delong M.R. Microstimulation of the primate neostriatum. 2. Somatotopic organization of striatal microexcitable zones and their relation to neuronal response properties. J. Neurophysiol. 53:1985;1417-1430.
2. Barbeau, A. Parkinson's disease: clinical features and etiopathology. In Vinken, Bruyn and Klawans (Eds.), Handbook of Clinical Neurology, Vol. 5 (49): Extrapyramidal Disorders, Elsevier, Amsterdam, 1986, pp. 87-152.
3. Baroni A., Benvenuti F., Fantini L., Pantaleo T., Urbani F. Human ballistic arm abduction movements: effects of L-DOPA treatment in Parkinson's disease. Neurology. 34:1984;868-876.
4. Benecke R., Rothwell J.C., Dick J.P.R., Day B.L., Marsden C.D. Simple and complex movements off and on treatment in patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 50:1987;296-303.
5. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological and neurochemical correlations. J. Neurol. Sci. 20:1973;415-455.
6. Brautigam K., Sohr R., Morgenstern R. 3-O-Methyl-DOPA is not involved in the development of behavioral supersensitivity after repeated L-DOPA administration of 6-OHDA lesioned rats. Behav. Brain Res. 63:1994;41-45.
7. Caligiuri M.P. Labial kinematics during speech in patients with parkinsonian rigidity. Brain. 110:1987;1033-1044.
8. Camarata P.J., Parker R.G., Park S.K., Haines S.J., Turner D.A., Chae H., Ebner T.J. Effects of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-induced hemiparkinsonism on the kinematics of a two-dimensional, multijoint arm movement in the rhesus monkey. Neuroscience. 48:1992;607-619.
9. Collins R.C. Kindling of neuroanatomic pathways during recurrent focal penicillin seizures. Brain Res. 150:1978;503-517.
10. Cotzias G.C., Papavasiliou P.S., Gellene R. Modification of parkinsonism - chronic treatment with L-DOPA. N. Engl. J. Med. 280:1969;337-345.
11. Cousins M.S., Salamone J.D. Involvement of ventrolateral striatal dopamine in movement initiation and execution: a microdialysis and behavioral investigation. Neuroscience. 70:1996;849-859.
12. Cousins M.S., Sokolowski J.D., Salamone J.D. Different effects of nucleus accumbens and ventrolateral striatal dopamine depletions on instrumental response selection in the rat. Pharmacol. Biochem. Behav. 46:1993;943-951.
13. Creasey H.M., Broe G. Parkinson's disease. J. Australia. 159:1993;249-252.
14. Doty R.L., Riklan M., Deems D.A., Reynolds C., Stellar S. The olfactory and cognitive deficits of Parkinson's disease: evidence for independence. Ann. Neurol. 25:1989;166-171.
15. Dunnett S.B., Iversen S.D. Sensorimotor impairments following localized kainic acid and 6-hydroxydopamine lesions of the neostriatum. Brain Res. 248:1982;121-127.
16. Evarts E.V., Teravainen H., Calne D.B. Reaction time in Parkinson's disease. Brain. 104:1981;167-186.
17. Evenden J.L., Robbins T.W. Effects of unilateral 6-hydroxydopamine lesions of the caudate-putamen on skilled forelimb use in the rat. Behav. Brain Res. 14:1984;61-68.
18. Factor, S.A., Weiner, W.J. The current clinical picture of Parkinson's disease. In F. Hefty and W.J. Weiner (Eds.), Progress in Parkinson Research, Plenum Press, New York, 1988, pp. 1-9.
19. Fairley P.C., Marshall J.F. Dopamine in the lateral caudate-putamen of the rat is essential for somatosensory orientation. Behav. Neurosci. 100:1987;652-663.
20. Fink J.S., Smith G.P. L-DOPA repairs deficits in locomotor exploration produced by denervation of catecholamine terminal fields in the forebrain of rats. J. Comp. Physiol. Psychol. 93:1979;66-73.
21. Greenamyre J.T. Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease. J. Neural. Transm. 91:1993;255-269.
22. Hardie R.J., Lees A.J., Stern G.M. On-off fluctuations in Parkinson's disease. Brain. 107:1984;487-506.
23. Hartelius L., Svennson P. Speech and swallowing symptoms associated with Parkinson's disease and multiple sclerosis: a survey. Folia Phoniatr. Logop. 46:1994;9-17.
24. Heindel W.C., Salmon D.P., Shults C.W., Walicke P.A., Butters N. Neuropsychological evidence for multiple memory systems: a comparison of Alzheimer's, Huntington's and Parkinson's disease patients. J. Neurosci. 9:1989;582-587.
25. Hornykiewicz, O. Dopamine and its physiological significance in brain function. In G.H. Browne (Ed.), The Structure and Function of Nervous Tissue, Academic Press, New York, 1972.
26. Hubbard C.A., Trugman J.M. Reversal of reserpine-induced catalepsy by selective D1 and D2 dopamine agonists. Movement Disord. 8:1993;473-478.
27. Jicha G., Salamone J.D. Vacuous jaw movements and feeding deficits in rats with ventrolateral striatal dopamine depletions: possible model of parkinsonian symptoms. J. Neurosci. 11:1991;822-3829.
28. Johnson M.T.V., Mendez A., Kipnis A.N., Silverstein P., Zwiebel F., Ebner T.J. Acute effects of levodopa on wrist movement in Parkinson's disease. Kinematics, volitional EMG modulation and reflex amplitude modulation. Brain. 117:1994;1409-1422.
29. Klockgether T., Dichgans J. Visual control of arm movement in Parkinson's disease. Movement Disord. 9:1994;48-56.
30. Klockgether T., Turski L., Honore T., Zhang Z., Gash D., Kurlan R., Greenamyre J.T. The AMPA receptor antagonist NBXQ has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Ann. Neurol. 30:1991;717-723.
31. Lange K.W., Riederer P. Glutamatergic drugs in Parkinson's disease. Life Sci. 55:1994;2067-2075.
32. Lazarus A., Stelmach G.E. Interlimb coordination in Parkinson's disease. Movement Disord. 7:1992;159-170.
33. Lees A.J. Dopamine agonists in Parkinson's disease: a look at apomorphine. Fund. Clin. Pharmacol. 7:1993;121-128.
34. Ljungberg T., Ungerstedt U. Reinstatement of eating by dopamine agonists in aphagic dopamine denervated rats. Physiol. Behav. 16:1974;277-283.
35. Longstreth W.T., Nelson L., Linde M., Munoz D. Utility of sickness impact profile in Parkinson's disease. J. Geriatr. Psychiatry Neurol. 5:1992;142-148.
36. Marsden C.D. The mysterious motor function of the basal ganglia: the Robert Wartenberg lecture. Neurology. 32:1982;514-539.
37. Marshall J.F., Richardson J.S., Teitelbaum P. Nigrostriatal damage and the lateral hypothalamic syndrome. J. Comp. Physiol. Psychol. 87:1974;808-830.
38. Marshall J.F., Levitan D., Stricker E.M. Activation-induced restoration of sensorimotor functions in rats with dopamine-depleting brain lesions. J. Comp. Physiol. Psychol. 90:1976;536-546.
39. McGeorge A.J., Faull R.L.M. The organization of the projection from the cerebral cortex to the striatum in the rat. Neuroscience. 29:1989;503-537.
40. Morelli M., Fenu S., Pinna A., DiChiara G. Opposite effects of NMDA receptor blockade on dopaminergic D1- and D2-mediated behavior in the 6-hydroxydopamine model of turning: relationship with c-fos expression. J. Pharmacol. Exp. Ther. 260:1992;402-408.
41. Pastor M.A., Jahanshahi M., Artieda J., Obeso J.A. Performance of repetitive wrist movements in Parkinson's disease. Brain. 115:1992;875-891.
42. Paul M.L., Graybiel A.M., David J.C., Robertson H.A. D1-like and D2-like dopamine receptors synergistically activate rotation and c-fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease. J. Neurosci. 12:1992;3729-3742.
43. Pisa M., Schranz J.A. Dissociable motor roles of the rat's striatum conform to somatotopic model. Behav. Neurosci. 102:1988;429-440.
44. Pullman S.L., Watts R.L., Juncos J.L., Chase T.N., Sanes J.N. Dopaminergic effects on simple and choice reaction time performance in Parkinson's disease. Neurology. 38:1988;249-254.
45. Rinne J.O. Nigral degeneration in Parkinson's disease. Movement Disord. 8:1993;s31-s35.
46. Sabol K.E., Neill D.B., Wages S.A., Church W.H., Justice J.B. Dopamine depletion in a striatal subregion disrupts performance of a skilled motor task in the rat. Brain Res. 335:1985;33-43.
47. Sakai K., Gash D.M. Effect of bilateral 6-OHDA lesions of the substantia nigra on locomotor activity in the rat. Brain Res. 633:1994;144-150.
48. Salamone, J.D. Strategies for drug development in the treatment of dementia. In P. Willner (Ed.), Behavioral Models in Psychopharmacology, Cambridge Univ. Press, Cambridge, UK, 1990, pp. 598-613.
49. Salamone J.D., Kurth P.A., McCullough L.D., Sokolowski J.D., Cousins M.S. The role of brain dopamine in response initiation: effects of haloperidol and regionally specific dopamine depletions on the local rate of instrumental responding. Brain Res. 628:1993;218-226.
50. Salamone J.D., Mahan K., Rogers S. Ventrolateral striatal dopamine depletions impair feeding and food handling in rats. Pharmacol. Biochem. Behav. 44:1993;605-610.
51. Salamone J.D., Zigmond M.J., Stricker E.M. Characterization of the impaired feeding behavior in rats given haloperidol or dopamine-depleting brain lesions. Neuroscience. 39:1990;17-24.
52. Schallert T., Whishaw I.Q., Ramirez V.D., Teitelbaum P. Compulsive, abnormal walking caused by anticholinergics in akinetic, 6-hydroxydopamine-treated rats. Science. 199:1978;1461-1463.
53. Stricker, E.M., Zigmond, M.J. Recovery of function after damage to catecholamine-containing neurons: a neurochemical model for the lateral hypothalamic syndrome. In J.M. Sprague and A.N. Epstein (Eds.), Progress in Psychobiology and Physiological Psychology, Academic Press, New York, 1976.
54. Svensson P., Henningson C., Karlsson S. Speech motor control in Parkinson's disease: a comparison between a clinical assessment protocol and a quantitative analysis of mandibular movments. Folia Phoniatr. Base. 45:1993;157-164.
55. Taylor J.R., Lawrence D.E., Redmond J.D., Elsworth J.D., Roth R.H., Nocols D.E., Mailman R.B. Dihydrexidine, a full dopamine D1 agonist, reduces MPTP-induced parkinsonism in monkeys. Eur. J. Pharmacol. 199:1991;389.
56. Ungerstedt U. Aphagia and adipsia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol. Scand. 82(Suppl. 367):1971;95-122.
57. Uretsky N.J., Schoenfeld R.I. Effect of L-DOPA on the locomotor activity of rats pretreated with 6-hydroxydopamine. Nature. 234:1971;157-159.
58. Velasco F., Velasco M. A quantitative evaluation of the effects of L-DOPA on Parkinson's disease. Neuropharmacology. 12:1973;89-99.
59. Vermulen R.J., Drukarch B., Sahadat M.C.R., Goosen C., Wolters E.C., Stoof J.C. The selective dopamine D1 receptor agonist, SKF 81297, stimulates motor behavior of MPTP-lesioned monkeys. Eur. J. Pharmacol. 235:1993;143-147.
60. Webster K.E. Cortico-striate interrelations in the albino rat. J. Anat. 95:1961;523-543.
61. Whishaw I.Q., O'Connor W.T., Dunnett S.B. The contribution of motor cortex, nigrosriatal dopamine and caudate-putamen to skilled forepaw use in the rat. Brain. 109:1986;805-843.
62. Wise S.P., Jones E.G. Cells of origin and terminal distribution of descending projections of the rat somatic sensory cortex. J. Comp. Neurol. 175:1977;129-158.
63. Zigmond, M.J., Stricker, E.M. Berger, T.W. Parkinsonism: insights from animal models utilizing neurotoxic agents. In Animal Models of Dementia, Alan R. Liss, New York, 1987, pp. 1-38.